Dr John Burke speaks to ecancer about the 12-month follow-up results from the phase II MorningSun study presented at ASH 2025. This study evaluates mosunetuzumab in patients with previously untreated high tumour burden follicular lymphoma.

Dr Burke reports that mosunetuzumab showed an 85.5% progression-free survival rate at 12 months, with a high overall response rate of 87.4%. The study also demonstrated promising outcomes in patients who received optional maintenance therapy, with 91.9% overall survival at 12 months.

He highlights the manageable safety profile, with common adverse events including injection site reactions, fatigue, and cytokine release syndrome. Dr Burke also reports that 86.4% of patients achieving a complete metabolic response were minimal residual disease negative, supporting the fixed-duration treatment approach. These findings affirm mosunetuzumab’s potential for outpatient use in community practices.